Agenus (AGEN) and Noetik announced a research collaboration to develop predictive biomarkers of response to Agenus' lead clinical stage immuno-oncology combination, botensilimab and balstilimab. The company noted that, central to this collaboration is Noetik's OCTO virtual cell model, a 1.5 billion parameter foundation model trained on one of the largest multimodal spatial datasets. The collaboration aims to uncover actionable biomarkers that can help predict which patients are most likely to respond to BOT/BAL treatment.
Garo Armen, CEO of Agenus, said: "By integrating Noetik's virtual cell models with our expansive BOT/BAL clinical dataset, we have the potential to accelerate the identification of predictive biomarkers, enhance the success of our pivotal trials, and ultimately improve outcomes for patients who currently have limited or no treatment options."
Noetik is an AI-native biotechnology company using machine learning to increase clinical success rates for precision cancer therapies.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.